Upfront Briefing
Candel led the weekend tape with extended phase 3 follow-up in localized prostate cancer ahead of a Q4 BLA, while Aardvark landed on the wrong side of the agency with a full clinical hold on its lead Prader-Willi asset. The wider mood was hardly serene: acting CDER chief Tracy Beth Høeg was fired Friday days after Makary's exit, leaving five different people running CDER inside 15 months and pushing the FDA-volatility premium back into biotech multiples.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,408.5 |
(1.2%) |
+8.0% |
| Nasdaq 100 |
29,125.2 |
(1.5%) |
+15.5% |
| Russell 2000 |
2,793.3 |
(2.4%) |
+11.4% |
| Healthcare (XLV) |
145.1 |
(1.0%) |
(6.7%) |
| Biotech (XBI) |
130.7 |
(3.1%) |
+7.5% |
| Nasdaq Biotech (NBI) |
5,825.5 |
(2.7%) |
+2.1% |
| Clinical Trials (BBC) |
42.4 |
(3.7%) |
+12.8% |
|
- Macro risk-off drove the tape: Brent +3.3% to ~$109 on Iran tensions, 10-year Treasury yields punched to 1-year highs, and traders fully priced out 2026 Fed cuts after a hot CPI print earlier in the week.
- Biotech took the higher-beta hit: XBI -3.1% and small-cap clinical names (BBC -3.7%) underperformed XLV (-1.0%) by ~2 points, compounded by Aardvark's ~30% slide on the FDA clinical hold.
- Market data: U.S. close Fri 15-May-2026.
The Big 3
|
1
|
Candel reports extended follow-up benefit in prostate cancer
|
- At AUA, Candel (CADL) reported extended phase 3 follow-up for aglatimagene besadenovec (CAN-2409) + standard-of-care EBRT in intermediate-to-high-risk localized prostate cancer, including a 90% reduction in time-to-metastasis vs placebo in the intermediate-risk subgroup (85% of the trial).
- Why it matters: CAN-2409 carries an SPA, RMAT and Fast Track and Candel has guided to a Q4 2026 BLA — durability + a clean metastasis signal tightens PoS into filing and re-rates the rNPV on a localized prostate franchise with no approved adenoviral immunotherapy comp.
- Source: Endpoints
- More: PR
|
|
2
|
Aardvark clinical hold triggers setback in Prader-Willi program
|
- FDA placed a full clinical hold on Aardvark's (AARD) lead asset ARD-101 — an oral bitter-taste receptor agonist that stimulates endogenous GLP-1 and CCK — escalating February's voluntary pause after reversible cardiac signals in a healthy-volunteer study. The phase 3 HERO trial (68 dosed) and OLE (19 dosed) in PWS hyperphagia are halted; Aardvark will unblind data to inform next steps. Stock closed -30% Friday.
- Why it matters: $91.2M cash funds operations into mid-2027, but the binary now shifts from peak sales to whether unblinded efficacy is strong enough to negotiate hold removal. PWS is a derisked commercial backdrop — Soleno's Vyktat is the only approved hyperphagia drug and Neurocrine bought Soleno ~12 months post-launch — but ARD-101 needs a defensible cardiac safety story before the bid floor reappears.
-
Source:
BioPharma Dive
-
More:
Endpoints
|
|
3
|
Acting CDER chief Høeg fired days after Makary's exit
|
- Tracy Beth Høeg — a vaccine and antidepressant skeptic elevated to acting CDER head in December — was fired Friday, six months into the role, per her own X post; deputy Mike Davis is now acting CDER director. She becomes the fifth person to run CDER in the 15 months of the current administration.
- Why it matters: CDER signs off on every NDA/BLA — turnover at the top of the division reviewing small molecules and biologics directly raises timing risk for PDUFA dates, advisory committee scheduling and Type B/C meetings. With Makary, Høeg and the CDC director all gone inside a week and CBER also unfilled, the FDA volatility premium hits cell/gene therapy, rare disease and any name with a 2H26 catalyst hardest.
- Source: Endpoints
- More: Reuters/US News; Endpoints (Makary recap)
|
Everything Else that broke
- JASCAYD wins approval in Japan for IPF and PPF. — PR
- Datar Cancer Genetics gets FDA clearance for CellDx-Tissue. — PR
- Novartis sees PSA-progression benefit for Pluvicto. — PR
- ImPact Biotech reports phase 3 ENLIGHTED data. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Lotte Biologics expanded its CDMO manufacturing agreement with UK-based Ottimo Pharma covering OTP-01, a PD-1/VEGFR2 biparatopic antibody for oncology; commercial process development at Lotte's Syracuse Bio Campus. — PR
- NeuroVision Imaging acquired fellow diagnostics player Durin Life Sciences (Duritect blood-based biomarker tests for Alzheimer's, Parkinson's, ALS) for undisclosed terms; Ric Edelman (Durin majority owner) joins the board. — Fierce Biotech
VC / Private Financings
- CellCentric raised $220M in a Series D to fund a pivotal Phase 3 myeloma trial for inobrodib in 2H26; syndicate included Venrock Healthcare Capital Partners, Pfizer, Fidelity, Sofinnova, RA Capital and Forbion. — BioSpace
IPOs / Follow-Ons
- No new biotech IPOs or material follow-ons priced over the weekend.
Academic Corner - Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. — Lancet
- End of transplantation's reign in mantle cell lymphoma. — Lancet
|
